AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Gonadotropin-releasing hormone receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P30968

UPID:

GNRHR_HUMAN

Alternative names:

-

Alternative UPACC:

P30968; O75793; Q14D13; Q92644

Background:

The Gonadotropin-releasing hormone receptor (GnRH-R) plays a pivotal role in the reproductive system. It binds to GnRH, triggering the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through a G-protein-coupled phosphatidylinositol-calcium second messenger system. Its isoform 2 can inhibit GnRH-R signaling, showcasing the receptor's complex regulatory mechanisms.

Therapeutic significance:

GnRH-R's involvement in Hypogonadotropic hypogonadism 7, a condition marked by delayed or absent sexual maturation and low gonadotropin levels, underscores its therapeutic potential. Targeting GnRH-R could lead to novel treatments for reproductive disorders, including those with anosmia or normosmic idiopathic hypogonadotropic hypogonadism (nIHH), by modulating hormone release.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.